Evidence map›Paper›PMID 26940611›Full record

ArticleAnnals of biomedical engineering2016

Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis.

Suwei Zhu, Tatiana Segura

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of biomedical engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Suwei ZhuDepartment of Chemical & Biomolecular Engineering, University of California Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA, 90095, USA.
Tatiana SeguraDepartment of Chemical & Biomolecular Engineering, University of California Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA, 90095, USA. tsegura@ucla.edu.
University of California, Los Angeles · US

Funding

VEGF Ligand Presentation and Therapeutic AngiogenesisR01NS079691 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEGURA, TATIANA · 2012 to 2024
$4.0M
Hydrogels for Local Gene Delivery and Therapeutic AngiogenesisR01HL110592 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEGURA, TATIANA · 2011 to 2015
$1.8M
HIGH-END CRYOEM INSTRUMENT FOR UCLA ELECTRON IMAGING CTR FOR NANOMACHINES: AIDSS10RR023057 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2006 to 2006
$1.6M
NCRR NIH HHS S10 RR023057NHLBI NIH HHS R01 HL110592NINDS NIH HHS R01 NS079691
6 · The paper itself

Abstract

Although the delivery of vascular endothelial growth factor (VEGF) with extended release profiles has consistently shown beneficial therapeutic effects compared with bolus delivery, [Martino, M. M., F. Tortelli, M. Mochizuki, S. Traub, D. Ben-David, G. A. Kuhn, R. Muller, E. Livne, S. A. Eming, and J. A. Hubbell. Sci. Transl. Med. 3(100):100ra189, 2011; Martino, M. M., P. S. Briquez, A. Ranga, M. P. Lutolf, and J. A. Hubbell. Proc. Natl. Acad. Sci. USA. 110(12):4563-4568, 2013; Amiram, M., K. M. Luginbuhl, X. Li, M. N. Feinglos, and A. Chilkoti. Proc. Natl. Acad. Sci. USA. 110(8):2792-2797, 2013] it remains unclear if the reason is solely due to the physical availability and the reduced degradation of the protein. Here we studied the activation of VEGF receptor 2 (VR-2) by sustained released VEGF compared with bolus delivered VEGF to unveil that sustained delivery system alters the dynamics of receptor activation and affects the actions of cells between sprouting and proliferation. We utilized a protein nanocapsule delivery strategy that releases VEGF as mediated by extracellular proteases. These protein nanocapsules were synthesized through an aqueous assembly of a nanogel-peptide shell around the protein, leading to one to two proteins encapsulated per nanocapsule. Receptor activation studies revealed differential dynamics of receptor activation for slowly released VEGF compared with bolus delivered VEGF. As expected sustained released VEGF via nanocapsules resulted in enhanced vascular sprouting in vitro and in vivo. These studies demonstrate the physical presentation of VEGF, in this case of a slow release with time, can affect its molecular mechanism of actions and cause alterations in cellular responses and therapeutic outcomes.

Indexed as

Immobilized ProteinsVascular Endothelial Growth Factor ADelayed-Action PreparationsHumansHuman Umbilical Vein Endothelial CellsNanocapsulesNeovascularization, PhysiologicVascular Endothelial Growth Factor Receptor-2Delayed-Action PreparationsImmobilized ProteinsKDR protein, humanNanocapsulesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanGrowth factorProtease-sensitiveSustained releaseWound repair

Identifiers

PMID26940611
PMCPMC4880527
OpenAlexW2292829186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.